IGF::OT::IGF -- Biomarkers for Alcohol and ALD

Echelon Biosciences, Inc., Salt Lake City UT

Investigators

Abstract

This contract addresses the need for reliable and accurate biomarkers of alcohol consumption, initially in response to a National Institute on Alcohol Abuse and Alcoholism (NIAAA)-initiated Small Business Innovation Research (SBIR) contract topic on Biomarkers for Alcohol-induced Disorders. The goals of this contract are to advance the usefulness of phosphatidylethanol (PEth), an alcohol metabolite, as a clinical biomarker of alcohol consumption, by designing an antibody-based method of quantitation that is cheaper and more accessible to small hospitals and clinics than currently used chromatographic/ spectrophotometric methods. This contract is a continuation of a Phase II SBIR contract with Echelon Biosciences, Inc. It was awarded under SBIR solicitation PHS-2008-1, Topic 031. This effort is deemed to be non-severable.